Results 41 to 50 of about 141,128 (314)

Clinical outcomes of submassive pulmonary embolism thrombolysis—an Indian experience

The Egyptian Heart Journal, 2020
Background Acute pulmonary thromboembolism is the most dangerous presentation of venous thromboembolic disease. The role of thrombolysis in massive pulmonary embolism has been studied extensively, but the same is not there for submassive pulmonary ...
Nadeem U. Rehman, Mohd Iqbal Dar, Manish Bansal, R. R. Kasliwal   +3 more
doaj   +1 more source

Using simulation and machine learning to maximise the benefit of intravenous thrombolysis in acute stroke in England and Wales: the SAMueL modelling and qualitative study

Health and Social Care Delivery Research, 2022
Background: Stroke is a common cause of adult disability. Expert opinion is that about 20% of patients should receive thrombolysis to break up a clot causing the stroke.
Michael Allen, Charlotte James, Julia Frost, Kristin Liabo, Kerry Pearn, Thomas Monks, Zhivko Zhelev, Stuart Logan, Richard Everson, Martin James, Ken Stein   +10 more
doaj   +1 more source

Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: individual-patient-data meta-analysis of randomized trials [PDF]

, 2017
Background: The recommended maximum age and time window for intravenous alteplase treatment of acute ischemic stroke differs between the Europe Union and United States.
Colin Baigent, Danilo Toni, Erich Bluhmki, Geoffrey A Donnan, Geoffrey Cohen, George Howard, Gregory Albers, Gregory del Zoppo, James C Grotta, Jean-Marc Olivot, Joanna M Wardlaw, Jonathan Emberson, Kazunori Toyoda, Kennedy R Lees, Lisa Blackwell, Maarten G Lansberg, Mark Parsons, Markku Kaste, Masatoshi Koga, Nils Wahlgren, null null, Patrick Lyden, Peter AG Sandercock, Richard I Lindley, Rüdiger von Kummer, Stephen M Davis, Thomas Brott, Werner Hacke, William N Whiteley   +28 more
core   +5 more sources

Epistaxis Versus Nonepistaxis Bleeding in Anticoagulated Patients With Atrial Fibrillation: Results From the ENGAGE AF‐TIMI 48 Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Epistaxis is common with antithrombotic therapy and is often troublesome to patients, yet its frequency, severity, and outcomes are poorly characterized.
Robert S. Semco, Regan W. Bergmark, Sabina A. Murphy, Abby L. Cange, Martin Unverdorben, Cathy Z. L. Chen, Christian T. Ruff, Elliott M. Antman, Robert P. Giugliano, Brian A. Bergmark   +9 more
doaj   +1 more source

Choices Regarding Thrombolysis Are Modified by the Way to Transfer the Messages

Frontiers in Neurology, 2017
Although thrombolysis is the most effective medical treatment for acute ischemic stroke, many stroke patients eligible for thrombolysis miss this treatment as a result of delay or refusal by the patients and/or their proxies. To explore the influences of
Jingjing Gong, Yan Zhang, Hongyan Gao, Wei Wei, Jing Lv, Hongyun Liu, Yonghua Huang   +6 more
doaj   +1 more source

Relationship of left ventricular outflow tract velocity time integral to treatment strategy in submassive and massive pulmonary embolism

Pulmonary Circulation, 2020
Pulmonary embolism is associated with high rates of mortality and morbidity. It is important to understand direct comparisons of current interventions to differentiate favorable outcomes and complications.
David Antoine, Taylor Chuich, Ruben Mylvaganam, Chris Malaisrie, Benjamin Freed, Michael Cuttica, Daniel Schimmel   +6 more
doaj   +1 more source

Association of the ICH Score With Withdrawal of Life‐Sustaining Treatment Over a 10‐Year Period

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The intracerebral hemorrhage (ICH) score was developed to enhance provider communication and facilitate early severity assessment. We examined the association of the ICH score with mortality and withdrawal of life‐sustaining treatment (WLST) in a large, multicenter stroke registry, and evaluated temporal trends in these associations.
Nina Massad, Lili Zhou, Brian Manolovitz, Negar Asdaghi, Hannah Gardener, Hao Ying, Carolina M. Gutierrez, Angus Jameson, David Rose, Mohan Kottapally, Amedeo Merenda, Kristine O'Phelan, Sebastian Koch, Jose G. Romano, Tatjana Rundek, Ayham Alkhachroum   +15 more
wiley   +1 more source

COST-EFFECTIVENESS EVALUATION OF PREHOSPITAL THROMBOLYSIS WITH TENECTEPLASE

Рациональная фармакотерапия в кардиологии, 2016
Aim. To evaluate clinical and cost effectiveness of different reperfusion strategies in myocardial infarction with ST segment elevation (STEMI), including pre-hospital thrombolysis with tenecteplase.  Material and methods.
V. V. Omel'yanovskiy, E. V. Derkach, P. M. Khaylov, S. N. Tereshchenko   +3 more
doaj   +3 more sources

Early recurrent ischemic stroke complicating intravenous thrombolysis for stroke: incidence and association with atrial fibrillation [PDF]

, 2010
<p><b>Background and Purpose:</b> Mechanisms of early neurologic deterioration after treatment with intravenous, recombinant, tissue-type plasminogen activator (IV rt-PA) include symptomatic intracerebral hemorrhage (SICH) and early ...
Awadh, M., Baird, T., MacDougall, N., Muir, K.W., Santosh, C., Teasdale, E.   +5 more
core   +1 more source

Circulating Interleukin‐6 Levels and Timing of Acute Ischemic Stroke Onset

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Intravenous thrombolysis is the most widely available effective ischemic stroke treatment, but is approved only if given within 4.5 h from stroke onset. Many patients are not treated because stroke onset time is unknown. We evaluated the cytokine interleukin 6 (IL‐6) in circulating blood after acute ischemic stroke (AIS).
Robert G. Kowalski, Aurélie Ledreux, John E. Violette, Whitney Paustian, Stefan Sillau, John A. Thompson, Robert T. Neumann, David Ornelas, Andrew A. Monte, Layne Dylla, Adit A. Ginde, Andra M. Farcas, Christina M. Coughlan, William J. Jones, James C. Grotta, Michael W. Graner   +15 more
wiley   +1 more source